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Does von Willebrand factor improve 
the predictive ability of current risk 
stratification scores in patients with 
atrial fibrillation?
Amaya García-Fernández1, Vanessa Roldán2, José Miguel Rivera-Caravaca3, 
Diana Hernández-Romero3, Mariano Valdés3, Vicente Vicente2, Gregory Y. H. Lip4,5,* & 
Francisco Marín3,*
Von Willebrand factor (vWF) is a biomarker of endothelial dysfunction. We investigated its role on 
prognosis in anticoagulated atrial fibrillation (AF) patients and determined whether its addition to 
clinical risk stratification schemes improved event-risk prediction. Consecutive outpatients with 
non-valvular AF were recruited and rates of thrombotic/cardiovascular events, major bleeding and 
mortality were recorded. The effect of vWF on prognosis was calculated using a Cox regression model. 
Improvements in predictive accuracy over current scores were determined by calculating the integrated 
discrimination improvement (IDI), net reclassification improvement (NRI), comparison of receiver-
operator characteristic (ROC) curves and Decision Curve Analysis (DCA). 1215 patients (49% males, age 
76 (71–81) years) were included. Follow-up was almost 7 years. Significant associations were found 
between vWF and cardiovascular events, stroke, mortality and bleeding. Based on IDI and NRI, addition 
of vWF to CHA2DS2-VASc statistically improved its predictive value, but c-indexes were not significantly 
different. For major bleeding, the addition of vWF to HAS-BLED improved the c-index but not IDI or 
NRI. DCA showed minimal net benefit. vWF acts as a simple prognostic biomarker in AF and, whilst its 
addition to current scores statistically improves prediction for some endpoints, absolute changes and 
impact on clinical decision-making are marginal.
Atrial fibrillation (AF) is increasingly more common and confers a five-fold increase in the risk of stroke1. AF 
patients also show high incidence of other cardiovascular events, such as acute coronary syndrome and cardio-
vascular death2 and a residual risk remains despite the use of oral anticoagulation (OAC)3. When compared to 
control, OAC with Vitamin K antagonists (VKA) reduces the risk of stroke by 64% and all-cause mortality by 
26%, with further reductions using non-VKA OACs (NOACs)4,5.
The risks of thromboembolism and bleeding in AF are heterogeneous and several risk stratification schemes 
have been developed to tailor the decision-making. Guidelines6,7 recommend the use of the CHA2DS2-VASc score 
[Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes mellitus, Stroke, Vascular disease, Age 65 to 64 
years, Sex category], as a simple, clinical risk factor-based approach to thromboprophylaxis8. This score has been 
validated in different cohorts and we have previously demonstrated that it is also predictive for vascular events 
and mortality in AF9. Nevertheless, the predictive value of the CHA2DS2-VASc and other clinical factor-based risk 
stratification schemes for identifying ‘high risk’ patients that develop events remains modest10. Nonetheless, the 
CHA2DS2-VASc has shown to reliably identify AF patients at truly low-risk of thromboembolism, who require no 
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antithrombotic therapy11. However, use of CHA2DS2-VASc results in a high proportion of patients treated with 
OAC, and most would experience no events12. CHA2DS2-VASc also does not incorporate all possible risk factors 
for embolism, such as renal impairment, nor detailed echocardiographic or biochemical parameters13.
On the other hand, OAC increases the risk of bleeding complications, the most serious of which is intracra-
nial haemorrhage4. Many stroke risk factors have also been identified as risk factors for bleeding10,14. Several risk 
stratification scores have been developed to estimate bleeding risk in AF15. For example, the HAS-BLED score 
(Hypertension, Abnormal renal/liver function, previous Stroke, previous Bleeding/predisposition, Labile INR, 
Elderly (age ≥ 65), concomitant Drugs or alcohol abuse), to assess the risk of major bleeding, and draw attention 
to revisable bleeding risk factors16.
Continuous efforts have been made to improve stroke and bleeding risk stratification in AF and various stud-
ies point out to a promising role of cardiac biomarkers to further refine these risks17,18.
Plasma glycoprotein von Willebrand factor (vWF) is synthesized mainly by endothelial cells in response to 
endothelial activation or damage, promoting platelet adhesion and aggregation at sites of vascular injury19. vWF 
has been considered an established marker of endothelial damage/dysfunction20. Increased plasma levels of vWF 
have been found in different inflammatory and atherosclerotic vascular diseases21, as well as in AF22,23, and is 
predictive of stroke and vascular events24. We have previously shown that high plasma vWF predicts adverse 
cardiovascular events, mortality and major bleeding in anticoagulated AF patients25.
In this study, we investigated the role of vWF on prognosis in relation to cardiovascular events, stroke and 
cardiovascular mortality, as well as major bleeding, in a large prospective ‘real-world’ cohort of anticoagulated 
patients with AF, and determined whether the addition of vWF to current clinical risk stratification schemes 
improved event-risk prediction.
Methods
Study patients. During the second semester of 2007 we recruited consecutive patients with non-valvular AF 
from our outpatient anticoagulation clinic in a tertiary hospital of south-eastern Spain. All the patients received 
VKA and needed to be stabilized for at least 6 months (international normalized ratio: 2.0–3.0), so at baseline the 
average time in therapeutic range (TTR) was 100%, to enable ‘anticoagulation status’ homogeneity of the baseline 
cohort. We excluded patients with valvular AF or prosthetic heart valves, as well as those with any acute coro-
nary syndrome, stroke, hemodynamic instability, hospital admissions or surgical interventions in the preceding 
6 months.
Data on baseline clinical characteristics were recorded at study entry. The CHA2DS2-VASc and the HAS-BLED 
scores were calculated using established definitions of the different risk factors, as previously described8,26. 
Follow-up was conducted by visits to our anticoagulation clinic. Adverse cardiovascular events were defined as 
follows: stroke/transient ischaemic attack, systemic and peripheral embolism, acute coronary syndrome, acute 
heart failure and cardiac death. The composite cardiovascular endpoint included all these events. Major bleeding 
events were assessed following the International Society of Thrombosis and Haemostasis criteria27. All-cause 
deaths were also recorded.
Blood samples and laboratory analysis. At study inclusion, blood samples were drawn atraumatically 
and without stasis into syringes pre-loaded with trisodium citrate (0.011 mol/l). Platelet-poor plasma fractions 
were obtained by centrifugation at 4 °C for 20 min at 2,200 g. Aliquots were stored at − 80 °C to allow batch 
analysis. Plasma vWF antigen levels were assessed in an automated coagulometer ACL Top 3G, HemosIL von 
Willebrand factor (Instrumentation Laboratory, Lexington, Massachusetts). The inter-assay and intra-assay coef-
ficients of variation were 1.4% and 9%, respectively, and the lower limits of detection were 2.2 IU/dl and 21 ng/ml, 
respectively.
Statistical analysis. Continuous variables were tested for normal distribution by the Kolmogorov-Smirnov 
test. Continuous variables are presented as a mean ± standard deviation or median (interquartile range), as 
appropriate, and categorical variables, as percentages. Receiver-operator characteristic (ROC) curve analyses (ie. 
c-indexes) were generated to test the predictive discrimination of vWF to identify association with adverse events 
during follow-up. The cut point with the best sensitivity and specificity for each adverse event was chosen. The 
independent effect of variables (vWF, CHA2DS2-VASc and HAS-BLED scores) on prognosis was calculated using 
a Cox proportional hazards regression model. Differences in event-free survival between patients with different 
levels of vWF were reflected by Kaplan-Meier curves.
To compare the predictive ability of risk-stratification schemes before and after adding vWF levels to the mod-
els, we calculated the statistical significance of the difference between the areas under the two ROC curves (AUC) 
with the method of DeLong et al.28. Also, improvement in the predictive accuracy of the models was evaluated by 
calculating the relative integrated discrimination improvement (IDI) and the net reclassification improvement 
(NRI), as described by Pencina et al.29.
We also estimated the clinical usefulness and net benefit of the new predictive models using decision curve 
analysis (DCA), as described by Vickers et al.30. This analysis identifies patients who will have any of the adverse 
events evaluated, based on the predictions of the modified risk score in comparison with the original. The x-axis 
shows threshold values for adverse event risk while the y-axis represents the net benefit for the different threshold 
values of adverse event risk. A higher net benefit is provided by those prediction models that are farthest away 
from the slanted dash grey line (i.e., assume all adverse events) and the horizontal black line (i.e., assume no 
adverse event).
A p value < 0.05 was accepted as statistically significant. Statistical analyses were performed using SPSS v. 15.0 
(SPSS, Inc., Chicago, IL, USA), MedCalc v. 16.4.3 (MedCalc Software bvba, Ostend, Belgium) and STATA v. 12.0 
(Stata Corp., College Station, TX, USA) for Windows.
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Ethical issues. This study was approved by the Ethical Committee of Morales Meseguer University Hospital 
and was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its 
later amendments. Patients gave their informed consent prior to their inclusion in the study.
Results
We included 1215 patients with non-valvular AF. Baseline characteristics of the patients are shown in Table 1. 
During a median follow-up of 2373 (IQR 1564–2892) days, 115 patients presented stroke (1.45%/year); 498 
patients died (6.30%/year) and 222 experienced major bleeding (2.81%/year). Annual rates of the different 
adverse events are summarized in Table 2.
Univariate and multivariate analysis. For each adverse event, we constructed a ROC curve for vWF 
levels, that gave a median cut-off point of 190 UI/dL [AUC: 0.60 (95%CI: 0.56–0.64); p < 0.001] for the composite 
cardiovascular end-point; 194 UI/dL [AUC: 0.60 (95%CI: 0.55–0.65); p < 0.001] for stroke; 184 UI/dL [AUC: 0.62 
(95%CI: 0.59–0.65); p < 0.001] for total mortality; 184 UI/dL [AUC: 0.64 (95%CI: 0.57–0.71); p < 0.001] for car-
diovascular mortality and 197 UI/dL [AUC: 0.61 (95%CI: 0.57–0.65); p < 0.001] for major bleeding.
Univariate and multivariate analysis for the different adverse events for vWF levels and stroke and bleed-
ing risk-stratification scores are shown in Table 3. On univariate analyses, plasma vWF levels were significantly 
predictive of cardiovascular events, stroke, all cause-mortality, cardiovascular death and major haemorrhage. 
CHA2DS2-VASc score significantly predicted the composite cardiovascular end-point, stroke, all-cause and car-
diovascular death, whilst HAS-BLED score was an independent predictor of major bleeding. After adjustment for 
the CHA2DS2-VAScscore, vWF levels were significantly associated with the incidence of the composite cardiovas-
cular end-point, stroke, all-cause mortality and cardiovascular mortality. Also, when we adjusted for HAS-BLED 
score, vWF was a significant predictor of major bleeding (Table 3). Figure 1 illustrates Kaplan-Meier plots for each 
outcome in relation to vWF levels (please see online supplement).
Additive effect of von Willebrand factor levels to clinical risk scores. Based on IDI and NRI, the 
addition of vWF to CHA2DS2-VASc statistically improved its predictive value for cardiovascular events, stroke 
and cardiovascular mortality, but C-indexes were not significantly different and remained modest (approx. 0.6). 
Median (IQR) N (%)
Age 76 (71–81)
Male sex 599 (49.3)
Hypertension 1002 (82.5)
Diabetes 320 (26.4)
Heart failure 378 (31.1)
Ischaemic heart disease 231 (19.0)
Smoking 183 (15.1)
Dyslipemia 393 (32.3)
Previous stroke 224 (18.4)
Previous bleeding 102 (8.4)
Alcohol abuse 39 (3.2)
Renal disease 125 (10.3)
Hepatic disease 14 (1.2)
Antiplatelet drugs 216 (17.8)
CHA2DS2-VASc score 4 (3–5)
HAS-BLED score 2 (2–3)
vWF levels (UI/dL) 189.7 (132.0–234.0)
Table 1.  Baseline characteristics of atrial fibrillation patients (N = 1215). IQR: interquartile range.
n (%) Annual rate (%)
Composite cardiovascular end-point* 226 (18.6) 2.90
Stroke 115 (9.5) 1.45
Total mortality 498 (41.0) 6.30
Cardiovascular death 76 (6.3) 0.96
Major bleeding 222 (18.3) 2.81
Intracranial haemorrhage 65 (5.4) 0.82
Mortality of bleeding episodes 45 (3.7) 0.56
Table 2.  Annual rate of the different adverse events. *Stroke-thromboembolism, acute coronary syndrome, 
acute heart failure and cardiovascular death.
www.nature.com/scientificreports/
4Scientific RepoRts | 7:41565 | DOI: 10.1038/srep41565
Whilst statistically significant, the change in IDI and NRI was small (< 1% increase) in its predictive ability for 
cardiovascular events, stroke and cardiovascular mortality (Table 4). For major bleeding, addition of vWF to 
HAS-BLED improved the c-index but not the IDI or NRI (Table 5).
DCA graphically shows minimal net benefit of the modified CHA2DS2-VASc and HAS-BLED scores, that does 
not justify their clinical use or impact on practical decision-making (Fig. 1).
Discussion
In this study of a large contemporary ‘real world’ cohort of stable anticoagulated non-valvular AF patients, 
we show that even if vWF acts as a simple prognostic biomarker and that the addition of vWF levels to the 
CHA2DS2-VASc and the HAS-BLED scores statistically improved prediction for some endpoints, absolute 
changes and clinical improvement or impact on clinical decision-making (using DCA) was marginal, with 
c-indexes all remaining modest (approx. 0.6).
Cardiac biomarkers have evolved as prognostic tools in different cardiovascular scenarios. The importance 
of vWF to cardiovascular disorders has been long recognised31. Raised levels of vWF have been described in 
AF individuals, compared to those in sinus rhythm23. Also, the prognostic role of plasma vWF in AF has been 
well-established32,33. In the Rotterdam Study, which included more than 6000 participants, the risk of stroke was 
associated with vWF levels in the general population, no matter AF was present or not34. Also, vWF appears to 
be able to identify, not only patients with high thromboembolic risk, but also subjects at risk of major bleeding 
and mortality. Indeed, major bleedings and death occur more frequently than embolism in anticoagulated AF 
patients, and in this study we show that bleeding rates doubled rates of stroke, and mortality was four times 
greater.
Other biomarkers, such us Growth Differentiation factor-15 (GDF-15, a marker of oxidative stress and inflam-
mation) and high-sensitivity Troponin T (hs-TnT), have also been shown to act as additive prognostic markers 
(at least statistically) for major bleeding and death in AF subjects with OAC35,36.
In the present study, we demonstrate that raised vWF levels doubled the risk of stroke, cardiovascular death 
and major bleeding, and increased (by more than 50%) cardiovascular events and all-cause mortality. We have 
previously shown that this biomarker acts as an independent risk factor for adverse events, including cardiovas-
cular events (stroke, acute coronary syndrome and acute heart failure), cardiovascular death, all cause mortality 
and major haemorrhagic episodes in a ‘real-life’ anticoagulated non-valvular AF population25. In another study, 
raised vWF activation factor levels (a modified test that detects vWF with high platelet affinity) correlated with 
all-cause mortality and cardiovascular events, but no association was observed with bleeding complications37. The 
same group had previously described an increased risk of bleeding complications, cardiovascular and all-cause 
mortality in patients with high levels of vWF during treatment with warfarin; nonetheless, only one third of the 
subjects in both studies had AF as the indication for OAC38.
Currently, the CHA2DS2-VASc score is recommended to assist clinical decision-making for OAC6,7, but 
its predictive value is modest8. In order to improve stroke risk stratification, composite risk prediction scores 
(CHA2DS2-VASc + HAS-BLED or CHADS2 + HAS-BLED) have been compared with separate individual 
scores, but they have not shown to significantly improve clinical prediction of thromboembolism and bleed-
ing39. Unsurprisingly, cardiac biomarkers could help to refine event-risk stratification in these patients. For exam-
ple, Lip et al. first showed that plasma vWF levels added to the CHADS2 and the Birmingham (precursor of 
CHA2DS2-VASc) schemes could help to refine risk stratification for vascular events (ischemic stroke, myocar-
dial infarction or vascular death) in AF patients enrolled in the SPAF III trial17; however, they were not able to 
identify an independent association with the risk of stroke. Recently, Hijazi et al. demonstrated that N-terminal 
fragment B-type Natriuretic Peptide (NT-proBNP) and hs-TnT improved risk stratification for stroke, cardiac 
death and bleeding beyond the CHA2DS2-VASc score36,40. This group then proposed the ABC score (which adds 
biomarkers to clinical factors) in a selected clinical trial cohort of AF patients anticoagulated with apixaban or 
warfarin from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial 
Fibrillation)41. In a similar manner, the ABC-bleeding score was also validated, including biomarkers (haemoglo-
bin, hsTnT and GDF-15 or cystatin C/glomerular filtration rate) and this score performed better than the (clinical 
Univariate analysis HR (95% CI) Multivariate analysis HR (95% CI)
Composite cardiovascular end-point1
CHA2DS2-VASc score 1.36 (1.26–1.48); p < 0.001 1.34 (1.23–1.46); p < 0.001
vWF > 190 UI/dL 1.96 (1.50–2.57); p < 0.001 1.77 (1.35–2.32); p < 0.001
Stroke1
CHA2DS2-VASc score 1.35 (1.20–1.51); p < 0.001 1.32 (1.18–1.49); p < 0.001
vWF > 194 UI/dL 2.19 (1.50–3.20); p < 0.001 1.98 (1.36–2.90); p < 0.001
All-cause mortality1
CHA2DS2-VASc score 1.33 (1.26–1.40); p < 0.001 1.30 (1.23–1.38); p < 0.001
vWF > 184 UI/dL 1.75 (1.46–2.10); p < 0.001 1.53 (1.28–1.84); p < 0.001
Cardiovascular death1
CHA2DS2-VASc score 1.49 (1.30–1.71); p < 0.001 1.46 (1.27–1.68); p < 0.001
vWF > 184 UI/dL 2.34 (1.44–3.80); p < 0.001 1.95 (1.20–3.18); p = 0.007
Major bleeding2
HAS-BLED score 1.45 (1.28–1.65); p < 0.001 1.39 (1.23–1.58); p < 0.001
vWF > 197 UI/dL 2.13 (1.62–2.79); p < 0.001 1.95 (1.49–2.57); p < 0.001
Table 3.  Cox analysis for vWF levels, the CHA2DS2-VASc and the HAS-BLED scores for the different 
endpoints. HR: hazard ratio. 1Variables included in multivariate analysis: CHA2DS2-VASc score and vWF 
plasma levels. 2Variables included in multivariate analysis: HAS-BLED score and vWF plasma levels.
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factor-based) HAS-BLED or ORBIT scores18. Whilst statistically significant improvement in prediction was seen, 
overall c-indexes still remain modest (approx. 0.6–0.7).
Contrary to this evidence from the highly selected trial patient cohorts, we have not been able to demonstrate 
that the addition of a biomarker (specifically, vWF) to clinical risk scores markedly improves decision making for 
event risk prediction, as DCA only showed minimal net benefit of the modifiedscores that incorporated biomark-
ers. Nonetheless, our study adds some novel strengths to the current knowledge in this field, amongst ‘real-world’ 
AF patients. In light of our data, even if vWF levels provide independent prognostic information, we cannot 
recommend the addition of vWF as a biomarker to the CHA2DS2-VASc and HAS-BLED risk scores in order to 
refine event-risk prediction.
More insights are needed to explore the role of cardiac biomarkers to aid clinical decision-making for throm-
boprophylaxis in AF. The continued preoccupation with trying to improve prediction of ‘high risk’ patients with 
ever more complex scores (and often multiple biomarkers), with only marginal improvement in predictive per-
formance, at the cost of simplicity and practicability, would seem counterintuitive for everyday clinical manage-
ment42. Meanwhile, a more simple strategy, using conventional clinical risk scores, should be the preferred option. 
In short, simplicity and practicability (and costs of biomarkers) should be balanced.
Figure 1. Decision curves for the original and modified risk scores (adding von Willebrand factor). 
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Limitations
Only a single determination of plasma vWF levels was made, at study entry, thus we cannot be sure if making 
other determinations during follow-up could have changed our results. Only patients on VKA were included, so 
our results may not be generalized to individuals receiving NOACs. TTR was 100% at study entry, but we do not 
have data of this parameter over the follow-up period, which could affect the occurrence of the adverse events. 
Although vWF levels are known to be associated to cardiovascular risk factors (such as hypertension or heart 
failure), we have previously shown that the association of this biomarker with adverse events in AF is independent 
of other clinical variables25.
Conclusions
In conclusion, vWF acts as a simple prognostic biomarker in anticoagulated AF patients and, whilst addition of 
vWF levels to the CHA2DS2-VASc and the HAS-BLED scores statistically improved prediction for some end-
points, the absolute changes and clinical value or impact on practical decision-making was minimal.
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